Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Background While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response f...

Full description

Bibliographic Details
Main Authors: Matthias Gromeier, Darell D Bigner, Smita K Nair, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Carol Ann Wiggs, Andrea True Kelly, April KS Salama
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/4/e002203.full

Internet

https://jitc.bmj.com/content/9/4/e002203.full

Similar Items